MedTrace Logo

Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers

NCT06613139 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-11-15

No results posted yet for this study

Summary

An open-label, randomized, single-dose, oral administration, 2-sequence, 2- period, crossover study to evaluate bioequivalence between YHP2305 and YHR2404 in healthy subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

YHP2305

Test drug: YHP2305 Comparator: YHR2404

DRUG

YHR2404

Test drug: YHP2305 comparator: YHR2404

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Taegon Hong · Locations

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-06
Primary Completion
2024-10-15
Completion
2024-10-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613139 on ClinicalTrials.gov